U.S. patent application number 11/984482 was filed with the patent office on 2008-06-19 for highly sulfated derivatives of k5 polysaccharide and their preparation.
Invention is credited to Pasqua Oreste, Giorgio Zoppetti.
Application Number | 20080146793 11/984482 |
Document ID | / |
Family ID | 11447035 |
Filed Date | 2008-06-19 |
United States Patent
Application |
20080146793 |
Kind Code |
A1 |
Oreste; Pasqua ; et
al. |
June 19, 2008 |
Highly sulfated derivatives of K5 polysaccharide and their
preparation
Abstract
The purification of the E. coli K5 polysaccharide by treatment
with isopropyl alcohol and elimination of lipophilic substances is
described. The purified product can be used to prepare, after
N-deacetylation, new N,O-sulfated polysaccharides with high degree
of sulfation.
Inventors: |
Oreste; Pasqua; (Milano,
IT) ; Zoppetti; Giorgio; (Milano, IT) |
Correspondence
Address: |
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON
VA
22203
US
|
Family ID: |
11447035 |
Appl. No.: |
11/984482 |
Filed: |
November 19, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10902285 |
Jul 30, 2004 |
|
|
|
11984482 |
|
|
|
|
10469037 |
Aug 26, 2003 |
6992183 |
|
|
PCT/IB02/00561 |
Feb 26, 2002 |
|
|
|
10902285 |
|
|
|
|
Current U.S.
Class: |
536/123.1 ;
435/101 |
Current CPC
Class: |
Y02A 50/473 20180101;
C08B 37/0075 20130101; A61P 35/04 20180101; Y02A 50/30 20180101;
C08B 37/0063 20130101; C07H 3/00 20130101; A61K 31/737
20130101 |
Class at
Publication: |
536/123.1 ;
435/101 |
International
Class: |
C07H 3/00 20060101
C07H003/00; C12P 19/04 20060101 C12P019/04 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 27, 2001 |
IT |
M12001 A000397 |
Claims
1. Pure K5 polysaccharide showing no signals in the region below
1.5 ppm of its: .sup.1H-NMR spectrum.
2. The K5 polysaccharide of claim 1, wherein nucleic acids are not
detectable in the UV spectrum at 260 nm and the protein content is
below 0.5%.
3. The process of claim 4 wherein (a1) a K5 from fermentation,
dissolved at a 5% concentration in 4 M sodium chloride solution at
4.degree. C., is treated with 1 volume of isopropanol; (a2) the
salt solution is brought to a 3 M concentration by addition of the
calculated amount of sodium chloride; (a3) the solution is left to
stand overnight at 4.degree. C.; and (a4) the product thus obtained
is isolated by centrifugation and the salts are eliminated by
ultrafiltration whereby a K5 polysaccharide free from lipophilic
substances is obtained.
4. A process for the purification of K5 polysaccharide which
comprises treating a K5 polysaccharide from fermentation with
isopropanol in a 2-5 M aqueous saline solution.
5. The process of claim 4 wherein said K5 starting material is
dissolved in said saline solution at a concentration of from 0.5 to
10% and said isopropanol is added in 1-3 volumes.
6. The process of claim 5 wherein said saline solution is a 2-5 M
aqueous sodium chloride solution.
7. The process of claim 4 wherein the K5 starting material is
dissolved in a 2-5 M sodium chloride solution at a concentration of
from 0.5 to 10%, treated with 1-3 volumes of isopropanol at a
temperature of 0-8.degree. C. and the thus obtained solution is
brought to 2-4 M by further addition of sodium chloride, whereby a
K5 polysaccharide free from lipophilic substances is obtained and
isolated by filtration or centrifugation.
Description
SUMMARY
[0001] The purification of the E.coli K5 polysaccharide by
treatment with isopropyl alcohol and elimination of lipophilic
substances is described. The purified product can be used to
prepare, after N-deacetylation, new N,O-sulfated polysaccharides
with high degree of sulfation.
BACKGROUND OF THE INVENTION
[0002] It is known that the capsular polysaccharide K5 isolated
from a E.coli strain (herein below simply called "K5") described by
W. F. Vann et al. (1981) in Eur. J. Biochem. 116, 359-364, shows
the same sequence as the biosynthetic precursor of heparin and
heparan sulfate (N-acetylheparosan) and is chemically constituted
by repetitive disaccharide units formed by D-glucuronic acid and
N-acetylglucosamine linked .alpha.1-4, while the disaccharide units
d-glucuronyl-N-acetylglucosamine are linked .beta. 1-4. The only
difference which is not important for the biological activities of
the K5 and its derivatives, between the heparin precursor
N-acetylheparosan and K5 polysaccharide, is the presence of a
double bond in position 4(5) at the non reducing end of some chains
of the polymer, as for instance described in EP 489647 and EP
544592 herein below mentioned.
[0003] After this first publication, other papers and patent
applications described the preparation of the E. coli K5
polysaccharide having molecular weight ranges from few thousand to
many hundred thousand Daltons. For example EP 333243, IT 1230785,
EP 489647, EP 544592, WO 92/17507, WO 102597, and the paper of M.
Manzoni et al. (1996), Journal Bioactive Compatible Polymers, 11,
301-311 are indicated.
DESCRIPTION OF THE PRIOR ART
[0004] According to the literature, the K5 from fermentation of E.
coli strains was purified to eliminate for example nucleic acids,
endotoxins, pyrogens or in general proteins by various
methodologies.
[0005] Thus, for example. W. F. Vann et al. (1981) purified the K5,
isolated for the first time, after precipitation with quaternary
ammonium salts, using three precipitations with 80% ethanol, in EP
333243, the purification is performed by precipitation with a
quaternary ammonium salt, extraction and isolation of the K5. In EP
489647 and EP 544598, the K5 is purified by precipitation with
ethanol and exclusion and/or ionic exchange chromatography.
According to WO 92/17507, the purification is performed by
precipitation with ethanol, dialysis and, after centrifugation of
the dialyzed solution and elimination of the solid, freeze-drying
of the resulting solution. According to M. Manzoni et al. (1996)
and to WO 01/02597, that describe a procedure for the preparation
of K5 by fermentation in a culture medium containing defatted soy,
salts and glucose, the purification of K5 is performed using 1M
NaCl solution, ultrafiltration and ionic exchange chromatography of
a solution containing K5 obtained by ethanol precipitation.
[0006] Furthermore, K5 from fermentation was chemically modified to
obtain heparin-like products. Thus, among the above mentioned
documents, WO 92/17507, EP 489647 and EP 544592 describe
N,O-sulfated K5 with low and high molecular weight having
anticoagulant and antithrombotic activities, IT 1230785 and WO
92/17507 describe N-deacetylated-N,O-sulfated derivatives of K5
having a certain number of glucuronic units epimerized to iduronic
units, WO 98/09636 describes N-deacetylated-N,O-sulfated K5 having
antimetastatic activity.
[0007] Finally, for the O-sulfation of N-sulfate K5, literature
teaches how to modulate the number of sulfate groups that can be
introduced on the hydroxy groups of the disaccharide unit.
Particularly, Casu et al. (1994) Carbohydrate Research, 263,
.271-284 describe the N-deacetylation of K5, the N-sulfation and
three methods of O-sulfation indicated as B, C and AC. According to
method C, in which the sulfation of the N-sulfate K5 is performed
using 10 mole equivalents of sulfating agent per free hydroxyl
group at a temperature of 25-55.degree. C. for a period of time
ranging from 1 to 24 hours, polysulfated compounds are obtained
after a further N-sulfation having a maximum sulfate carboxyl ratio
of 3.1 that herein below will be indicated as N,O-oversulfated
K5.
[0008] The other K5 derivatives described herein below are also
designated as follow: "N-deacetylated K5" the N-deacetylated K5
polysaccharide, "N-sulfate K5" the N-deacetylated-N-sulfated K5
polysaccharide, "N,O-sulfate K5" the N-deacetylated-N,O-sulfated K5
polysaccharide and "N,O-oversulfated K5" the
N-deacetylated-N,O-sulfated K5 polysaccharide with high degree of
sulfation, for example obtained according to the above mentioned
Method C described by Casu et al. (1994).
SUMMARY OF THE INVENTION
[0009] Performing the O-sulfation of the N-sulfate K5 according to
the Method C it was observed that while in the case of heparin-like
compounds (i.e. having a certain percentage of uronic units as
iduronic acid) and in the case of K5 it is possible to achieve a
high degree of sulfation, in the case of N-sulfate K5 the
N,O-oversulfated K5 obtained showed a degree of sulfation which did
not reach 3.2 sulfate groups per disaccharide unit. This evidence
explains the lacking of literature reference to N,O-oversulfated K5
having more than 3.2 sulfate groups per disaccharide unit, products
potentially interesting for their high anionic degree.
[0010] It was now been found that by purifying the K5 obtained by
fermentation by treatment with isopropanol in a highly saline
solution, a pure K5 polysaccharide is obtained, practically free of
lipophilic substances.
[0011] Moreover it was found that by submitting the K5 free of
lipophilic substances thus obtained to a N-deacetylation, to a
N-sulfation, to a O-sulfation according to the Method C and,
optionally, to another N-sulfation, new N,O-oversulfated K5
compounds having a sulfation degree higher than 3.2 and in general
equal to or higher than 3.5 are obtained.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1 shows the .sup.1H-NMR spectrum of K5 obtained from
fermentation with a 80% purity.
[0013] FIG. 2 shows the .sup.1H-NMR spectrum of K5 obtained from
fermentation free of lipophilic substances with a purity
>99%.
DETAILED DESCRIPTION OF THE INVENTION
[0014] Thus, according to one of its aspects, the present invention
provides a process for the preparation of new N,O-oversulfated K5
having a sulfation degree higher than 3.2 which comprises [0015]
(a) treating a K5 obtained from fermentation with isopropanol in a
highly saline aqueous solution; [0016] (b) submitting the thus
purified K5 to a N-deacetylation by alkaline hydrolysis and to a
subsequent N-sulfation by treatment with a N-sulfating agent;
[0017] (c) treating the ammonium salt of the N-sulfate K5 thus
obtained with an O-sulfating agent under the O-oversulfation
conditions; and [0018] (d) if required, submitting the compound
thus obtained to a N-regulation and isolating N,O-oversulfated K5
as sodium salt, which is optionally converted to another salt.
[0019] The term "sulfation degree" designates the number of sulfate
groups per disaccharide unit, expressed as sulfate/carboxyl
ratio.
[0020] The term O-oversulfation means the oversulfation of the
N-sulfate K5, obtained for example by using the Method C.
[0021] In step (a), the K5 used as starting material can be one of
the products obtained by fermentation of wild or cloned Escherichia
Coli strains producing K5. In particular the K5 described in
literature like those above cited can be used, advantageously those
described by M. Manzoni et al. Journal Bioactive Compatible
Polymers 1996, 11, 301-311 and the one illustrated in PREPARATION I
herein below.
[0022] More advantageously, the K5 starting material has a low
molecular weight, in particular with a distribution of from about
1,500 to about 15,000, preferably from about 2,000 to about 9,000,
with a mean molecular weight of about 5,000, or a higher molecular
weight, in particular with a distribution of from about 10,000 to
about 50,000, preferably from about 20,000 to about 40,000 and a
mean molecular weight of about 30,000. Preferably the K5 starting
material has a molecular weight distribution of from about 1,500 to
about 50,000, with a mean molecular weight of 20,000-25,000.
[0023] The molecular weight of K5 and of its derivatives here
described is intended calculated using fractions of heparin with
known molecular weight as standards; all the molecular weights in
the present invention are expressed in Dalton.
[0024] The starting material can be a previously purified K5 from
which, for example, the endotoxins, the pyrogens o other impurities
have been eliminated with known methodologies.
[0025] Likely, if the K5 obtained at the end of passage (a) is used
for pharmaceutic purposes or for the preparation of N,O-sulfate K5
for pharmaceutical use, it can be purified from pyrogens and
endotoxins.
[0026] Practically, the K5 starting material is dissolved in a 2-5
M solution, preferably of sodium chloride, at a concentration of
from 0.5 to 10% and treated with 1-3 volumes of isopropanol at a
temperature of 0-8.degree. C. and the thus obtained solution,
brought to 2-4 M by the further addition of salt, preferably sodium
chloride.
[0027] After 1-18 hours at the same temperature, the product of
step (a) completely precipitates and is isolated by filtration or
centrifugation. If the purity of the product is not satisfactory,
the procedure of step (a) is repeated. The solid product thus
obtained is redissolved in water and recovered by ultrafiltration
with a membrane.
[0028] At the end of step (a) a K5 having the same characteristics
as those of the starting material, but being substantially free of
lipophilic substances is obtained.
[0029] Practically, the K5 free of lipophilic substances is
obtainable by a process which comprises (a1) treating a K5 from
fermentation, dissolved in a 4 M solution of sodium chloride at
4.degree. C. with 1 volume of isopropanol, (a2) bringing the saline
solution to 3 M by adding the calculated amount of a sodium
chloride saturated solution, (a3) keeping the solution at 4.degree.
C. overnight and (a4) isolating the product by centrifugation and
eliminating the salts by ultrafiltration.
[0030] By the purification with isopropanol it is thus possible to
obtain a K5 free of lipophilic substances which has a purity higher
than 99%. This K5 allows to obtain a high O-sulfation in the next
step (c).
[0031] In step (b), the N-deacetylation is performed according to
the known methods of alkaline hydrolysis, for example with
hydrazine sulfate in hydrazine or with a base such as an alkaline
hydroxide, for example sodium or potassium hydroxide, in water.
Preferably the reaction is performed in an aqueous solution of
sodium hydroxide at a temperature of 40-80.degree. C., by
controlling the course of the reaction. In general, after at most
30 hours, but practically after 12-24 hours the N-deacetylation is
complete and the alkalinity of the medium is neutralized by
treatment with an acid, preferably hydrochloric acid.
[0032] The solution containing the K5 and the salts is subsequently
treated with a N-sulfating agent such as the adduct of a tertiary
organic base with sulfuric anhydride (sulfur trioxide), such as
pyridine.sulfur trioxide (C.sub.5H.sub.5N.SO.sub.3) or a
trialkylamine.sulfur trioxide such as trimethylamine.sulfur
trioxide in the presence of an alkaline carbonate such as sodium
carbonate. The reaction can be performed at room temperature
(20-30.degree. C.), but it is also possible to work at higher
temperatures (up to about 65.degree. C.) to shorten the reaction
time. The addition of the alkaline carbonate and of the sulfating
agent can be performed concurrently or the alkaline carbonate is
introduced in bulk and the sulfating agent is added subsequently,
stepwise, in a period of time which can last from 5 minutes to 12
hours. At the end of the reaction the mixture, at room temperature,
is brought to pH 7.5-8 by an acid, preferably hydrochloric acid and
the salts are eliminated for example by diatiltration. The so
obtained solution, containing the N-sulfate K5 as an alkaline salt,
can be passed to the subsequent step (c), or it can be concentrated
and the N-sulfate K5 can be isolated as sodium salt with
conventional methods. The thus obtained N-sulfate K5 is 90-100%
sulfated.
[0033] In step (c) a solution containing the alkaline N-sulfate K5
obtained in step (b) is neutralized for example by passage on a
cationic exchange resin, like IR 120 H.sup.+ till acid pH. The
acidic solution so obtained is treated with a tertiary or
quaternary organic base, for example with a trialkylamine like
tributylamine, or with the hydroxide of a tetralkylammonium,
preferably tetrabutylammonium hydroxide, reduced to the minimum
volume and freeze dried. The thus isolated ammonium salt of the
N-sulfate K5 is suspended in a polar aprotic solvent such as
dimethylformamide or dimethylsulfoxide and treated with an
O-sulfating agent, for example with the adduct
C.sub.5H.sub.5N.SO.sub.3. The adduct C.sub.5H.sub.5N.SO.sub.3 can
be used either in the solid state or in solution in the same polar
aprotic solvent. The sulfation is performed at a temperature that
can vary from the room temperature (20-30.degree. C.) to 70.degree.
C., preferably from 40 to 60.degree. C., for a period of time of
from 2 to 24 hours.
[0034] At the end of the faction, the solution at room temperature
is treated with sodium chloride saturated acetone till complete
precipitation. The precipitate is separated from the solvent by
filtration, dissolved in the minimum amount of deionized water, for
example 100 ml, and sodium chloride is added to the solution till a
0.2 M concentration. The solution is brought to pH 7.5-8 with 2N
sodium hydroxide and treated with acetone till complete
precipitation. After filtration the solid is dissolved in 100 ml of
deionized water and purified from the residual salts by
ultrafiltration as described in step (b).
[0035] If from the analysis by .sup.13C-NMR of a lyophilized sample
of the thus obtained product a partial N-desulfation occurred
during the oversulfation, the product is submitted to step (d).
[0036] In step (d) the product obtained at the end of step (c) is
treated with a N-sulfating agent by operating under the conditions
of step (b) till complete N-sulfation, repeating the procedure if
the N-sulfation is not complete.
[0037] The N,O-oversulfated K5 thus obtained is isolated as sodium
salt, that can be transformed into another salt, like potassium,
calcium, magnesium, aluminum, zinc or complex salts using known
methods, for example by ionic exchange with a suitable resin, by
precipitation with solvents or by ultrafiltration with
membranes.
[0038] According to another of its aspects, the present invention
provides a pure K5 from fermentation, substantially free of
lipophilic substances.
[0039] The purity of the new purified K5 from fermentation can be
assayed by .sup.1H-NMR spectrum, by UV spectrum, by carbazole
reaction or by a kit for the protein determination. By these assays
it was demonstrated that the K5 obtained at the end of step (a)
has, as the essential characteristic, a .sup.1H-NMR spectrum in
which signals in the field below 1.5 ppm are absent. Moreover the
nucleic acids are not detectable, (absorbance 0 at 260 nm with a
standard UV spectrophotometer) and the proteins are not higher than
0.5%, advantageously below 0.25%, more advantageously below 0.1%,
preferably below 0.03% according to BioRad kit.
[0040] Actually, the new pure K5 obtained at the end of step (a) is
free from lipophilic substances and nucleic acids. The use of
"substantially", referred to the absence of lipophilic substances
and of "not detectable" referred to the nucleic acids takes in
account the sensitivity of the instruments used which have not
revealed the presence of the above mentioned impurities.
[0041] Thus it was established that the .sup.1H-NMR spectrum of the
pure K5 polysaccharide obtained in this way lacks the signals at
<1.5 ppm characteristics of the methyl group of lipophilic
substances.
[0042] The new thus purified K5 compounds, which allow the
preparation of N,O-oversulfated K5 with a high degree of sulfation
have preferably a low molecular weight, in particular with a
distribution of from about 1,500 to about 15,000, preferably from
about 2,000 to about 9,000, with a mean molecular weight of about
5,000, or a higher molecular weight, in particular with a
distribution of from about 10,000 to about 50,000, preferably from
about 20,000 to about 40,000 with a mean molecular weight of about
30,000. Preferably the K5 starting material has a molecular weight
distribution of from about 1,500 to about 50,000 with a mean
molecular weight of 20,000-25,000.
[0043] Thus, according to another of its aspects, the present
invention provides new N,O-oversulfated K5 compounds having a
degree of sulfation higher than 3.2 and their salts. Advantageously
the new N,O-oversulfated K5 polysaccharides have a degree of
sulfation of from 3.2 to 4, more advantageously from 3.5 to 4,
preferably from 3.7 to 4. Preferably the salts of the new
N,O-oversulfated K5 are pharmaceutically acceptable.
[0044] Advantageously said N,O-oversulfated K5 have a low molecular
weight, in particular with a distribution of from about 2,000 to
about 16,000, preferably from about 2,500 to about 10,000 with a
mean molecular weight of about 6,500, or a somewhat higher
molecular weight, in particular with a distribution of from about
13,000 to about 65,000, preferably from about 25,000 to about
50,000 with a mean molecular weight of about 40,000. Preferably the
N,O-oversulfated K5 of the present invention has a molecular weight
distribution of from about 2,000 to about 65,000, with a mean
molecular weight of 25,000-30,000. Also N,O-oversulfated K5
compounds having a very low mean molecular weight, for example of
from about 2,000 to 5,000, obtained by depolymerization, constitute
very interesting products.
[0045] The depolymerization that allows the preparation of the
N,O-oversulfated K5 of mean molecular weight of from 2,000 to 5,000
can be performed at the end of one of steps (b)-(d) of the process
illustrated above, preferably at the end of step (b) or on the
final N,O-oversulfated K5.
[0046] The depolymerization can be performed according to one of
the known methods for the depolymerization of heparin, for example
by nitrous acid and subsequent reduction with sodium borohydride
(EP 37319), by periodate (EP 287477), by free radicals (EP 121067)
or by .beta.-elimination (EP 40144). According to a preferred
embodiment, the depolymerization is performed on a N-sulfate K5
obtained at the end of step (b) with nitrous acid and subsequent
reduction with sodium borohydride as detailed in EP 544592. At the
end of the depolymerization and reduction, the low molecular weight
product thus obtained is submitted to steps (c) and, optionally,
(d) and the N,O-oversulfated K5 is isolated.
[0047] Alternatively, the same process of depolymerization and
reduction can be applied to a N,O-oversulfate K5 with high
molecular weight and the corresponding low molecular weight product
is obtained straightforwardly.
[0048] Among the salts of the above mentioned N,O-oversulfated K5
compounds, the sodium, potassium, calcium, magnesium aluminum and
zinc salts are preferred.
[0049] According to a further aspect, the present invention
provides novel N,O-oversulfated K5 polysaccharides having a degree
of sulfation higher than 3.2, in particular from 3.2 to 4,
advantageously from 3.5 to 4, preferably from 3.7 to 4, obtainable
by a process which comprises [0050] (a) treating a K5 from
fermentation with isopropanol in a highly saline solution. [0051]
(b) submitting the thus obtained K5 to a N-deacetylation by
alkaline hydrolysis and to a subsequent N-sulfation by treatment
with a N-sulfating agent; (c) treating an ammonium salt of the
N-sulfate K5 thus obtained with an O-sulfating agent in the
O-oversulfation conditions; [0052] (d) if needed, submitting the
product thus obtained to a N-sulfation and isolating the
N,O-oversulfated K5 as sodium salt which, if necessary, is
converted into another salt.
[0053] The N,O-oversulfated K5 obtainable by the above mentioned
process have a degree of sulfation of from 3.2 to 4, advantageously
from 3.5 to 4, preferably from 3.7 to 4.
[0054] The new N,O-oversulfated K5 compounds obtained according to
the process of the present invention, especially as salts thereof,
are highly anionic products useful in the cosmetic industry as co
adjuvant against the loss of hairs and in the pharmaceutical
industry as products able to catch the free radicals.
[0055] Said N,O-oversulfated K5 compounds are completely sulfated
in the positions 6-O- and 2-NH- of the glucosamine units whilst in
the glucuronic units they are 2,3-O-disulfated or (2-O- or
3-O)monosulfated the percent of the sulfate groups in the
glucuronic units depending upon the sulfation degree.
[0056] Thus, it is a further object of the invention to provide
novel N,O-oversulfated K5 constituted by a mixture of chains in
which at least 90% of said chains are represented by the following
formula (I)
##STR00001##
wherein n is 3 to 100 and R and R' are hydrogen or a SO.sub.3.sup.-
group, at least one of R and R' being other than hydrogen, with the
proviso that [0057] R and R are both SO.sub.3.sup.- in from 60 to
100% of the n units; [0058] one of R and R' is hydrogen and the
other is SO.sub.3.sup.- in from 0 to 40% of the n units; the
sulfation degree being from 3.2 to 4 and the corresponding cation
being a chemically or pharmaceutically acceptable one.
[0059] In this context, the expression "chemically acceptable" is
referred to a cation which is useful for possible further
syntheses, such as ammonium or (C.sub.1-C.sub.4)trialkylammonium
ion, or for the purification of the product, preferred cations
being the above-mentioned sodium, potassium, magnesium, aluminum
and zinc ions.
[0060] In the remaining up to 10% chains in said mixture of chains,
for a given sulfation degree a certain amount of SO.sub.3.sup.-
groups of glucosamine units may have been splitted off from the
2-position and transferred onto the 3-OH group of said glucosamine
units.
[0061] Their high anion content confers to the N,O-oversulfated K5
polysaccharides of the present invention a good activity against
the free radicals. Due to their low toxicity they are useful active
ingredients for the preparation of pharmaceutical and cosmetic
compositions.
[0062] Thus, the present invention also provides pharmaceutical
compositions containing, as an active ingredient thereof, a
pharmacologically active amount of a N,O-oversulfated K5 having a
sulfation degree higher than 3.2, advantageously from 3.2 to 4,
more advantageously from 3.5 to 4, preferably from 3.7 to 4 or one
of its pharmaceutically acceptable salts in admixture with a
pharmaceutical recipient.
[0063] In the pharmaceutical compositions of the present invention
for the oral, subcutaneous, intravenous, intramuscular, transdermic
or topical administration, the active ingredients are preferably
administered in dosage units, in admixture with the classic
pharmaceutical carriers or vehicles.
[0064] The dosage can vary in function of the age, weight, and
health conditions of the patient. This dosage includes the
administration of a dose of from 1 to 1,000 mg, advantageously from
10 to 750 mg, preferably from 250 to 500 mg, from one to three
times per day by intravenous, subcutaneous, oral, intramuscular,
transdermic or topical route.
[0065] According to another of its aspects, the present inventions
relates a cosmetic composition containing, as one of its active
ingredients, a N,O-oversulfated K5 having a degree of sulfation
higher than 3.2, advantageously from 3.2 to 4, more advantageously
from 3.5 to 4, preferably from 3.7 to 4, or one of its
pharmaceutical acceptable salts, in admixture with a cosmetic
excipient.
[0066] A salt chosen among the group consisting in the sodium,
potassium, calcium, magnesium, aluminum and zinc salts constitutes
valid active ingredient of the compositions of the present
invention.
[0067] Finally, according to a further aspect, the present
invention also provides pharmaceutical and cosmetic compositions
comprising the new purified K5 of the invention as an active
ingredient.
PREPARATION I
Preparation of the K5 Polysaccharide from Escherichia Coli
[0068] First a fermentation in flask using the following medium is
performed:
TABLE-US-00001 Defatted soy 2 g/l K.sub.2HPO.sub.4 9.7 g/l
KH.sub.2PO.sub.4 2 g/l MgCl.sub.2 0.11 g/l Sodium citrate 0.5 g/l
Ammonium sulfate 1 g/l Glucose 2 g/l Water 1,000 ml pH = 7.3
[0069] The medium is sterilized at 120.degree. C. for 20 minutes.
The glucose is prepared separately as a solution which is
sterilized at 120.degree. C. for 30 minutes and added to the medium
under sterile conditions. The flask is inoculated with a suspension
of E. Coli cells Bi 8337/41 (O10:K5:H4) from a slant maintained in
Tryptic soy agar, and incubated at 37.degree. C. for 24 hours under
controlled stirring (160 rpm, 6 cm of run). The bacterial growth is
measured counting the cells with a microscope. In a further step, a
Chemap-Braun fermentor with a volume of 14 liters containing the
same medium above is inoculated with the 0.1% of the above flask
culture and the fermentation is performed with 1 vvm aeration (vvm
air volume for liquid volume for minute), 400 rpm stirring and
temperature of 37.degree. C. for 18 hours. During the fermentation
pH, oxygen, residual glucose, produced K5 polysaccharide and
bacterial growth are measured. At the end of the fermentation the
temperature is raised to 80.degree. C. for 10 minutes. The cells
are separated from the medium by centrifugation at 10,000 rpm and
the supernatant is ultrafiltrated through a SS316 (MST) module
equipped with PES membranes with a nominal cut off of 800 and
10,000 D to reduce the volume to 1/5. Then K5 polysaccharide is
precipitated adding 4 volumes of acetone at 4.degree. C. and left
to sediment for one night at 4.degree. C. and finally is
centrifuged at 10,000 rpm for 20 minutes or filtrated. Then a
deproteinization using a protease of the type II from Aspergillus
orizae in 0.1M NaCl and 0.15 M ethylenediaminotetracetic acid
(EDTA) at pH 8 containing 0.5% sodium dodecyl sulfate (SDS) (10
mg/l of filtrate) at 37.degree. C. for 90 minutes is performed. The
solution is ultrafiltrated on a SS 316 module with a nominal cut
off membrane of 10,000 D with 2 extractions with 1M NaCl and washed
with water until the absorbance disappears in the ultrafiltrate. K5
polysaccharide is then precipitated with acetone and a yield of 850
mg/l of fermentor is obtained. The purity of the polysaccharide is
measured by uronic acid determination (carbazole method), proton
and carbon NMR, UV and protein content. The purity is higher than
80%. The so obtained polysaccharide is composed of two fractions
with different molecular weight, 30,000 and 5,000 D respectively as
obtained from the HPLC determination using a 75 HR Pharmacia column
and one single fraction with retention time of about 9 minutes
using two columns of Bio-sil SEC 250 in series (BioRad) and
Na.sub.2SO.sub.4 as mobile phase at room temperature and flow rate
of 0.5 ml/minute. The determination is performed against a curve
obtained with heparin fractions with known molecular weight.
[0070] The .sup.1H-NMR of the purified K5 thus obtained is reported
in FIG. 1.
[0071] As it is possible to note, in the region below 1.5 ppm a lot
of signals attributable to the methyls of lipophilic substances are
present.
EXAMPLE 1
K5 Purification
[0072] In 100 ml of an aqueous solution containing 4M sodium
chloride and thermostated at 4.degree. C. are dissolved 5 gr of the
K5 obtained at the end of PREPARATION I and I volume of cold
isopropanol is added to the thus obtained solution. The salt
concentration of the solution is brought to 3 M by adding a
calculated amount of a saturated solution of sodium chloride and
the cooled solution is kept at cold temperature (about 4.degree.
C.) overnight. The precipitate formed is separated by
centrifugation at 10,000 rpm for 20 minutes and the purity of the
product is controlled by dialysis for one night and subsequent
.sup.1H-NMR analysis from which signals in the region below 1.5 ppm
must be absent. If necessary, the procedure of dissolution in water
containing 4M NaCl and precipitation with isopropanol is repeated.
The precipitate is dissolved in water and ultrafiltrated on a
Miniplate membrane Millipore with a 10,000 D cut off till
disappearance of the salts. A K5 having a purity of at least 99%
and whose .sup.1H-NMR spectrum is reported in FIG. 2 is
obtained.
[0073] As it can be noted, in the region below 1.5 ppm there are no
trace of lipophilic impurities.
[0074] The protein content calculated by using BioRad kit is 0.02%
and the nucleic acids are not detectable (absorbance 0 at 260
nm).
EXAMPLE 2
Preparation of a N,O-oversulfated K5
[0075] (i) N-deacetylation
[0076] Ten grams of pure K5 polysaccharide prepared as described in
Example 1 are dissolved with 1,000 ml of 2 N sodium hydroxide and
the solution thus prepared is kept at 60.degree. C. for 24 hours.
The solution is brought to room temperature and then to neutral pH
with 6N hydrochloric acid.
[0077] (ii) N-sulfation
[0078] To the solution containing the deacetylated K5, kept at
40.degree. C., 16 g of sodium carbonate and subsequently, in 4
hours. 16 g of pyridine.sulfur trioxide are added. At the end of
the reaction, after 24 hours, the solution is brought to room
temperature and then to pH 7.5-8 with a 5% solution of hydrochloric
acid. The product is purified from salts by diafiltration using a
spiral membrane of 1,000 D (Prepscale Cartridge-Millipore). The
process is ended when the conductivity of the permeate is below
1,000 .mu.S, preferably below 100 .mu.S. The intradialysis is
reduced till a polysaccharide concentration of 10% using the same
dialysis system in concentration. The concentrated solution is
freeze dried. The analysis of the .sup.13C-NMR does not show
N-acetyl or NH.sub.2 residual groups.
[0079] (iii) O-oversulfation
[0080] The freeze dried product obtained at the end of step (ii) is
dissolved in 100 ml of deionized water and the solution is brought
to 10.degree. C. with a cooling bath then passed onto a cationic
exchange resin IR120H.sup.- (100 ml). Both the column and the
reservoir are kept at 10.degree. C. After the passage of the
solution containing the sample the resin is washed with deionized
water till the pH of the permeate is higher than 6 (about 3 volumes
of deionized water). The acidic solution is brought to neutrality
(pH 7) with tetrabutylammonium hydroxide (15% aqueous solution),
then reduced to the minimum volume and freeze dried. The
tetrabutylammonium salt is dissolved in 400 ml of dimethvlformamide
and added with 35 g of C.sub.5H.sub.5N.SO.sub.3 in solid form. The
solution is kept at 50.degree. C. for 24 hours. At the end of the
reaction the solution is cooled to room temperature and added with
3 volumes of sodium chloride saturated acetone, cooled to 4.degree.
C. till complete precipitation (12 hours). The precipitate is
separated from the solvent by filtration, solubilized with the
minimum amount of deionized water (about 100 ml) and to the
solution sodium chloride till 0.2 M concentration is added.
[0081] The solution is brought to pH 7.5-8 with 2N sodium hydroxide
and treated with 2 volumes of acetone till complete precipitation.
The precipitate is separated from the solvent by filtration. The
solid obtained is solubilized with 100 ml of deionized water and
purified from the residual salts by ultrafiltration as described in
step (ii) using a spiral membrane of 1,000 D (Prepscale Cartridge
Millipore).
[0082] (iv) N-sulfation
[0083] The solution thus obtained, containing the O-sulfated
product, is treated as previously described in step (ii) for the
N-sulfation. The product shows a mean molecular weight of 15,000 D
and a sulfate/carboxyl ratio of 3.84. The distribution of the
sulfate groups, determined by the .sup.13C-NMR is the following:
the glucosamine unit of the constitutive disaccharide is 100%
N-sulfated and 6-0 sulfated, while, as to the glucuronic units, 30%
are monosulfated and 70% disulfated.
EXAMPLE 3
Preparation of a N,O-oversulfated K5
[0084] As starting material a K5 obtained and characterized as
described by M. Manzoni et al. (1996) is used. The K5 thus prepared
is purified as described in example 1 and a pure K5 in which the
signals below 1.5 ppm are absent, free of nucleic acids and with a
protein content of 0.5% is obtained. By operating as described in
Example 2 a N,O-oversulfated K5 having mean molecular weight of
13,000 and a sulfate to carboxyl ratio of 3.54 is obtained.
* * * * *